We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Elixirr International Plc | LSE:ELIX | London | Ordinary Share | GB00BLPHTX84 | ORD 0.005P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 780.00 | 10,720 | 08:00:27 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 770.00 | 790.00 | 780.00 | 780.00 | 780.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Management Consulting Svcs | 85.89M | 17.24M | 0.3646 | 21.39 | 368.73M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:52:54 | O | 320 | 780.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 25/11/2024 | 07:00 | UK RNS | Elixirr International PLC Change of Adviser |
| 31/10/2024 | 07:00 | UK RNS | Elixirr International PLC PDMR Dealings |
| 25/10/2024 | 11:27 | ALNC |  IN BRIEF: Elixirr directors and others sell GBP25 million in shares |
| 25/10/2024 | 11:01 | UK RNS | Elixirr International PLC Director/PDMR Shareholding |
| 25/10/2024 | 06:00 | UK RNS | Elixirr International PLC Result of Secondary Placing |
| 24/10/2024 | 15:35 | UK RNS | Elixirr International PLC Proposed Secondary Placing |
| 21/10/2024 | 08:47 | ALNC | Elixirr International boosts US presence with Hypothesis acquisition |
| 21/10/2024 | 06:00 | UK RNS | Elixirr International PLC Acquisition of Hypothesis Group, LLC |
| 14/10/2024 | 11:08 | ALNC | IN BRIEF: Elixirr agrees revolving credit facility with NatWest |
| 14/10/2024 | 06:00 | UK RNS | Elixirr International PLC Revolving Credit Facility |
Elixirr (ELIX) Share Charts1 Year Elixirr Chart |
|
1 Month Elixirr Chart |
Intraday Elixirr Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 06/11/2024 | 16:32 | Elixirr, an award-winning global challenger consultancy | 92 |
| 12/12/2023 | 18:15 | ELIXIRR The Challenger Consultancy | 126 |
| 11/10/2023 | 12:13 | ELIXIRR - The Challenger Consultancy - 2023 | 9 |
| 09/7/2020 | 18:13 | ELIXRR The Challenger consultancy | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:52:55 | 780.00 | 320 | 2,496.00 | O |
| 15:47:45 | 777.00 | 504 | 3,916.08 | O |
| 15:24:34 | 780.00 | 2,256 | 17,596.80 | O |
| 15:24:34 | 780.00 | 3,386 | 26,410.80 | O |
| 15:20:20 | 777.26 | 127 | 987.12 | O |
| Top Posts |
|---|
Posted at 03/12/2024 08:20 by Elixirr Daily Update Elixirr International Plc is listed in the Management Consulting Svcs sector of the London Stock Exchange with ticker ELIX. The last closing price for Elixirr was 780p.Elixirr currently has 47,272,811 shares in issue. The market capitalisation of Elixirr is £368,727,926. Elixirr has a price to earnings ratio (PE ratio) of 21.39. This morning ELIX shares opened at 780p |
Posted at 05/11/2024 17:22 by eagle eye That dip didn't last long did it.ELIX certainly knows how to shake weak holders out! |
Posted at 26/10/2024 23:24 by masurenguy The short term price mutability is irrelevant. The placing was done at 650p, which was 7% below the closing price on the day before the placing was announced. However, 650p was where the shareprice was circa 2 weeks ago. Over the past year the shareprice is up by around 40%. The price really only matters on the day that you buy or sell the shares. |
Posted at 26/10/2024 17:26 by silverlandfinance If selling shareholders receive the money, then existing shareholders are disatvanaged as the share price was over £7 before the placing.The only (questionable) advantage to them is that market in the shares is broader. |
Posted at 25/10/2024 06:18 by masurenguy Placing of Existing Ordinary Shares in the Company to satisfy strong institutional demandElixirr International plc announces that, further to its announcement released yesterday regarding a placing of existing shares via accelerated bookbuild ("ABB"), it has closed the ABB and confirms placement of the maximum amount of £25.0m through the placing of 3,846,153 existing ordinary shares of 0.005 pence each ("Ordinary Shares") in the capital of Company at a price of 650p per Placing Share (the "Placing") in order to satisfy strong institutional demand. Cavendish Capital Markets Limited ("Cavendish") is acting as sole bookrunner ("Bookrunner") in relation to the Placing. A further announcement noting the number of Placing Shares sold by and subsequent holdings of the Selling Shareholders who are also Directors or PDMRs of the Company will be made shortly. |
Posted at 21/10/2024 07:22 by masurenguy Cavendish raises target price by 8.7% on Hypothesis acquisition.Elixirr has acquired Hypothesis, a US-based consultancy, for an initial consideration of $37m on an EV/EBITDA multiple of 7.3x, and a maximum EV/EBITDA multiple of 8.8x if all deferred consideration is payable. Their top clients include 5 of the top 7 megacap technology companies and numerous Fortune 500 companies with many of their existing client relationships maintained for more than a decade. The acquisition is a very strong deal, expanding their scale in the US and we have upgraded our FY 2025 estimates by 9% and our target price from 998p to 1085p. |
Posted at 23/9/2024 06:19 by masurenguy Cavendish target price of 998pThis represents a 20% discount to Accenture on a 2024E EV/EBIT basis. Elixirr’s current FY 2024E EV/EBIT of 9.6x (11.0x fully diluted) and 2-year EBIT growth CAGR to 2025E of +14% compares to Accenture’s 20.9x and +5.4%. Elixirr offers nearly 3x the pace of growth for half the valuation. |
Posted at 29/8/2024 13:50 by mginvestor Lovely to see ELIX breaking out, how the share price has remained so cheap on a PE basis is beyond me. Maybe investors are beginning to realise that it's not all doom & gloom in MC's. In fact it may actually be very profitable being a shareholder in these type of businesses.Results end of Sep |
Posted at 30/12/2023 12:25 by mirabeau This year I am recommending a riskier small company with experienced top management, excellent growth prospects and a number of blue-chip clients. The company is Elixirr International (Aim: ELIX), a consultancy with a market value of £220m and a 2022 turnover of £70.7m, up by 40% on 2021.Elixirr was founded in 2009 by the current CEO, Stephen Newton, who had been a managing partner at Accenture. Newton says Elixxir’s ambition is to become the best digital, data, artificial intelligence (AI) and strategy consultancy in the world, with a globally recognised client base. It already numbers Diageo, HSBC, LVMH and Tesla among its clients. Elixirr features in several categories of the Financial Times’ 2023 list of the leading UK management consultancies. Its emphasis on digital, data and AI should shield it from the recent turndown in general consultancy. Elixirr grows organically and through bolt-on acquisitions such as US generative AI firm Responsum, which has enhanced the group’s AI capabilities. Revenue rose by 23% to £41.1m in the six months to 30 June, with pre-tax profits up 17% to £9.9m and net cash at £19.5m. Newton, who holds 28.7% of the shares (aligning his interests with other shareholders’) The trailing 12-month p/e is 17.5 and the forward dividend yield is 2.23% at the recent share price of 472p – well below analysts’ one-year price target of 868p. |
Posted at 11/12/2023 08:05 by masurenguy Acquisition of Insigniam LLC and Insigniam SAS.Elixirr International is pleased to announce the acquisition by its US subsidiary, Elixirr, Inc. of all of the issued and outstanding membership interests of Insigniam LLC, and by Elixirr International plc, of the entire issued and outstanding shares of Insigniam SAS, for a maximum consideration payable of US$18.5m. Acquisition highlights -- Insigniam is a US-headquartered consultancy firm with 50+ personnel specialising in supporting clients and executives to define and navigate large scale change and transformation. -- This is the Group's fifth acquisition since its IPO in July 2020 and third in the US, enhancing the Group's presence in this key market. -- In the 12 months to November 2023 (unaudited), Insigniam recorded revenue of US$13.7m, normalised EBITDA of US$2.3m and normalised profit before tax of US$2.3m. -- The initial consideration represents a multiple of 5.7x 2023 LTM EBITDA, based off November 2023 LTM financials (unaudited). -- The transaction is immediately earnings-enhancing. -- The Acquisition brings specialist services in transformation, leadership alignment, cultural change, and executive coaching, complementing the Group's existing service offerings. -- In addition to an expansion of capabilities, Insigniam has deep expertise in additive industries for Elixirr, and in particular has built a reputation as market leaders within industries such as healthcare, biopharmaceuticals, life sciences, consumer and retail. Insigniam also has a significant presence and client-base in continental Europe, complementing the Group's presence in this region. -- Insigniam's top clients include Fortune 500 companies and household brands, many of which are maintained through the leadership's long-standing relationships with the C-suite, coupled with its unique service offering. -- During due diligence and client interviews, Insigniam was found to be rated 43% better than their competition and has an NPS score of 66 - 85% of its clients report that Insigniam provides more value than any other consulting firm. Together with Insigniam, Elixirr will be able to enhance its existing service offering to its global client base. -- The US acquisition goodwill will be tax-deductible, resulting in an estimated tax benefit of US$2.8m-$4.3m to be realised over 15 years. Information on Insigniam and reasons for the Acquisition Insigniam helps companies navigate large-scale, complex change and transformation. Its offering includes leadership alignment, organisational transformation, cultural change and executive coaching, and its unique methodologies are used to break down performance barriers for C-suite teams across industries. Insigniam operates within a broadly unaddressed and in-demand white space in the market, through a dual focus on catalysing breakthrough change and achieving return on investment. This distinctive market opportunity is a key reason for the acquisition, especially when coupled with Insigniam's proven success at delivering for clients over its 35+ year history. Elixirr leadership believes that both firms' blue-chip clients stand to benefit from a joint proposition between Insigniam and Elixirr. Insigniam was co-founded by Shideh Sedgh Bina and Nathan Owen Rosenberg, both of whom will continue to spearhead the growth of the business alongside Elixirr moving forward. Shideh and Nathan will join the Group as Elixirr partners, alongside Katerin Le Folcalvez and Jennifer Zimmer. In the 12 months to November 2023 (unaudited), Insigniam recorded revenue of US$13.7m, normalised EBITDA of US$2.3m and normalised profit before tax of US$2.3m. Consideration for the Acquisition The Group acquired Insigniam for a maximum consideration payable of US$18.5m. The Consideration consists of: - Initial consideration of US$11.6m, from Elixirr's existing cash balances; - Initial consideration of US$1.5m to be settled through the issue in December 2023 of 258,553 Elixirr International plc Ordinary shares at a price per share of £4.60 by 15 December 2023. - Deferred consideration of up to US$5.4m in either cash or Ordinary Shares of Elixirr with, at a minimum, 33% of the deferred consideration being satisfied in cash. This is contingent on Insigniam achieving both revenue growth and EBITDA margin targets in financial periods up to 31 December 2026. - Based off November 2023 LTM financials (unaudited), this constitutes a Day 1 EV/EBITDA multiple of 5.7x, and a maximum EV/EBITDA multiple of 8.1x if all deferred consideration is earned over the three year period. - The Ordinary Shares will be subject to one-year lock-in arrangements and limitations on the Ordinary Shares that each seller can sell in each of the following three years under nominee agreements. Following the acquisition of Insigniam, Elixirr will have net cash of approximately £13.5m. Partner Promotions As part of its strategy to align incentives for senior personnel, Elixirr is pleased to announce that three recently promoted Partners will each be subscribing for 107,527 Ordinary Shares in the Company at a £4.65 share price. The Ordinary Shares issued to the new Partners will be subject to one-year lock-in arrangements and limitations on the Ordinary Shares that each Partner can sell in each of the following four years. In total, Elixirr will issue an additional 322,581 Ordinary Shares to promoted Partners. Application will be made to the London Stock Exchange for the New Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective at 8.00 a.m. on 15(th) December 2023. After Admission, the total number of Ordinary Shares in issue will be 47,272,811 and the total number of voting rights will therefore be 47,272,811. |
Posted at 06/11/2023 11:41 by simon gordon On the iOLAP website they have twenty vacancies, business must be strong.Thought this a decent summary: Investors Chronicle - 7/9/23 A capital-light consultancy with excellent momentum Boutique consultancies do not often crop up on the public market. Pay attention when they do. by Jemma Slingo “The concept of a structured work-life balance almost seems to be expected in today’s society – especially in a typical 9-to-5 role, but I think it should be seen as a privilege.” So says Stephen Newton, founder and chief executive of Elixirr (ELIX), a management consultancy that joined Aim three years ago. It’s a fitting message from an entrepreneur set on driving growth and trimming the fat. Elixirr presents itself as a new breed of management consultancy. It used a recent ad campaign to lampoon the industry’s jargon, swagger and reliance on under-experienced Oxbridge graduates, and continually stresses its “challenger&rd Punching above its weight With a market cap of under £250mn, Elixirr is small – even compared with specialist listed consulting peers such as Alpha Financial Markets Consulting (AFM) and XPS Pensions (XPS). However, it benefits from a similarly capital-light business model and excellent momentum. Indeed, according to Investec, Elixirr is the fastest-growing management consultancy in the UK and the third-fastest in Europe. Having increased its market share every year since 2011 and posted organic revenue growth of 18 per cent in 2022, Elixirr has momentum. With an adjusted Ebitda (earnings before interest, tax, depreciation and amortisation) margin at around 30 per cent, it is also profitable. The company was founded in the aftermath of the financial crash, and originally focused on financial services work, which is Newton’s area of expertise. Around half of group turnover still comes from the sector, but Elixirr is rapidly diversifying, and its 200-strong client base now includes names as varied and big-ticket as Diageo, LVMH, Tesla and Burger King. The fact that big names are on board suggests this youthful small cap is an increasingly viable alternative to the ‘Big Four’ professional services firms and strategy houses such as McKinsey, Boston Consulting Group and Bain, which together account for almost half of the market. A lot of the people who work at Elixirr cut their teeth in this world, so they know what they’re up against. Newton was formerly a managing partner at Accenture, while chief financial officer Graham Busby worked in Accenture’s ‘global mega-deal’ department. The quality of the wider management team is also encouraging, with former BT chief executive Gavin Patterson acting as non-executive chair. The big question is whether Elixirr can keep luring talented people away from the corporate behemoths. The group has about 500 consultants but just 21 of them are client-facing partners. As partners generate the biggest invoices and bring in most of the work, swelling their ranks will be crucial for growth. In this sense, Elixirr has a lot in common with Keystone Law (KEYS), whose success relies on a team of 400 senior solicitors and which has seen recruitment slow down in recent months. However, while Keystone’s self-employed “principals&rd Management claims that partners can earn 80 per cent more at Elixirr than they could at a big rival firm because, while cash remuneration is lower, the money saved on pay packets is pumped back into the business, fuelling equity returns. “By investing £3.2mn in the business over five years and assuming 25 per cent compound annual growth rate (CAGR) share price growth, each partner can achieve an equity return of £7.2mn,” declares Elixirr, which loans new partners £500,000 to buy shares. It concludes that over a five-year period a partner can earn £9mn (including cash remuneration) compared with £5mn at a Big Four firm. Non-partners are also strongly equity incentivised via share options and an employee share purchase plan. On the one hand, this approach makes a lot of sense. One of the big conundrums posed by listed people businesses is how to align the interests of partners with those of external investors. Why would partners want to return profit to shareholders if they could distribute it all among themselves? Elixirr’s focus on equity means everyone is singing from the same hymn sheet. However, its logic falls apart if shares head south and partners watch their pay prospects wither. Share dilution is therefore something to watch for. Management stressed that the “value created from our equity incentive schemes far outweighs the potential dilutive effect” and analysts note that there has been no material dilution to the share count since April 2021. As the business keeps scaling up, however, it remains a risk. Growing pains Organic growth is not Elixirr’s only option, of course. It recently deployed some cash to acquire iOLAP, a US consultancy specialising in data and analytics. The deal makes strategic sense and is reminiscent of Alpha FMC’s Lionpoint purchase. Elixirr now has a sizable presence in the US, home to the world’s biggest consultancy market, and should benefit from plenty of cross-selling opportunities. It’s not easy to scale up a business at pace however, and Alpha FMC’s recent performance spotlights some of the problems that Elixirr could face. Fears about under-utilised consultants marred Alpha FMC’s latest annual results, where the group cited industry-wide “increased levels of competition as a result of overcapacity”. Its shares have fallen by 25 per cent since the start of the year after a bumper three-year period. Elixirr has a more varied client base than Alpha FMC, but it is not immune to market conditions. Staff costs as a percentage of revenues have risen over the past four years, and margins could suffer if work dries up. To make things worse, it is tricky to predict when or if a downturn is coming as contracts only last for four to eight weeks on average, limiting visibility and management’s capacity to plan. The firm’s resilience has been tested before, though: in 2020, the group achieved revenue growth of 24 per cent while the consulting market as a whole shrank by 18 per cent. Elixirr’s balance sheet is also reassuringly robust. The group has a net cash position, despite several acquisitions and dividend payments, and operations have proved reliably cash-generative so far: standard payment terms require settlement of invoices within 30 days of receipt, and the majority of trade receivables are less than 31 days old. Valuing potential Elixirr's share price has risen by 165 per cent since its IPO, so potential investors can be forgiven for feeling as though they’ve missed the boat. Small-cap valuations are slippery at the best of times, and the lack of publicly traded consultancies – together with a dearth of analyst coverage – makes valuing Elixirr even harder. However, there does appear to be a disconnect between its growth prospects and its price/earnings (PE) multiple. Analysis by Investec puts Elixirr on a PE ratio of 15.4 for the 2023 calendar year, despite a forecast sales CAGR for 2022-24 of 17 per cent. By contrast, Alpha FMC is expected to grow by 10 per cent but trades on a PE ratio of 18.1. Some will argue that Elixirr is cheap because it is small and risky. It has a short track record on the public market and is not widely covered by analysts. It is also exposed to partner and client exits, and its top three clients account for about a fifth of sales. On balance, however, the risk-reward balance looks enticing. As a capital-light sector challenger, Elixirr’s momentum could well persist for years to come. Taken together, profitable growth, a burgeoning client base and US expansion plans make for an intoxicating mixture. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
